| Nov 6 |
Novo Nordisk Slumps On Tightened Outlook As Wegovy Beats, But Ozempic Lags
|
| Nov 6 |
Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
|
| Nov 6 |
Strong Wegovy revenue growth for Novo Nordisk but shares dip
|
| Nov 6 |
How to play healthcare stocks on Trump's win
|
| Nov 6 |
Novo Nordisk, in a mixed-bag earnings report, beat expectations on Wegovy sales but tightened its 2024 outlook
|
| Nov 6 |
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
|
| Nov 6 |
Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Transcript
|
| Nov 6 |
Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript
|
| Nov 6 |
Top Midday Stories: Big Tech, Tesla Likely to See Boost From Trump Win, Wedbush Says; Novo Nordisk Shares Fall on Q3 Sales Miss
|
| Nov 6 |
Novo Nordisk Dominates Obesity Market as Wegovy Sales Soar 76%
|
